Journal Article10.1056/NEJMOA061894
High-dose atorvastatin after stroke or transient ischemic attack.
Pierre Amarenco,Julien Bogousslavsky,Callahan A rd,Larry B. Goldstein,M.G. Hennerici,Amy E. Rudolph,Henrik Sillesen,Lisa Simunovic,Michael Szarek,K M Welch,Justin A. Zivin,Stroke Prevention by Aggressive Reduction in Cholesterol Levels (Sparcl) Investigators +11 more
2.6K
TL;DR: In this paper, the authors showed that 80 mg of atorvastatin per day reduced the overall incidence of stroke and cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke.
read more
Abstract: Background Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. Methods We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. Results The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. Conclusions In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke.
Mitchell S.V. Elkind,Ralph L. Sacco,Robert B. MacArthur,Daniel J. Fink,Ellinor I.B. Peerschke,Howard Andrews,Greg Neils,Josh Stillman,Tania Corporan,Dana Leifer,Ken Cheung +10 more
TL;DR: This early phase trial will be to determine the maximal-tolerated dose of lovastatin for short-term acute stroke therapy and the primary safety outcome will be occurrence of myotoxicity.
64
Multifunctional actions of approved and candidate stroke drugs
TL;DR: The mechanisms of action of agents approved for secondary prevention of ischemic stroke, such as antiplatelet, antihypertensive, and lipid-lowering drugs are described, which exhibit considerable properties beyond their classical mechanisms, including neuroprotective and neuroregenerative properties.
64
Aspirin in Alzheimer’s Disease Increased Risk of Intracerebral Hemorrhage: Cause for Concern?
Hanneke Thoonsen,Edo Richard,Peter Bentham,Richard Gray,Nan van Geloven,Rob J. de Haan,Willem A. van Gool,Paul J. Nederkoorn +7 more
TL;DR: The findings suggest that aspirin use in AD might pose an increased risk of ICH, whereas it has no effect on cognition, and if there is an unequivocal cardiovascular indication for aspirin, it should be withheld in AD patients.
64
Management of intracerebral hemorrhage
TL;DR: A systematic approach to the background, pathology, and early management of spontaneous parenchymal hemorrhage is provided and offers many areas for further investigation.
63
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
Roy W. Jones,Miia Kivipelto,Howard Feldman,Larry Sparks,Rachelle S. Doody,David D. Waters,Judith Hey-Hadavi,Andrei Breazna,Rachel Schindler,Harry Ramos,LEADe investigators +10 more
TL;DR: The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor.
63
References
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
Andrew Tonkin,P. Alyward,David Colquhoun,Paul Glasziou,P. Harris,D. Hunt,Anthony C Keech,Stephen MacMahon,P. Magnus,D. Newel,P. Nestel,N. Sharpe,J. Shaw,R. J. Simes,P. Thompson,Alexis A. Thompson,Malcolm J. West,H. White,S. Simes,Wendy Hague,Sue Caleo,Jane Hall,Andrew J. Martin,S. Mulray,Philip J. Barter,Lawrence J. Beilin,Rory Collins,John J McNeil,Petra Meier,H. Willimott,D. Smithers,P. Wallace,J. Baker,M. Hobbs,David R. Sullivan,N. Anderson,Graeme J. Hankey,John D.G. Watson,M. Arulchelvam,S. Chup,John Daly,J. Hanna,A. Leach,M. Lee,J. Loughhead,H. Lundie-Jenkin,J. Morrison,S. Netting,A. Nguyen,H. Pater,R. Philip,G. Pinna,D. Rattos,S. Ryerson,V. Sazhin,Richard Walsh,A. Claque,M. Mackie,Julie Jane Yallop,K. Boss,M. Shepard,J. Leach,M. Gandy,J. Joughin,J. Seabrook,R. Abraham,J. Allen,F. Bates,I. Beinart,E. Breed,D. Brown,N. Bunyan,D. Calvert,T. Campbell,D. Condon-Paoloni,B. Conway,Lucy A. Coupland,J. Crowe,N. Cunio,B. Cuthbert,N. Cuthbert,S. D'Arcy,Patricia M. Davidson,B. Dwyer,J. England,C. Friend,Greg Fulcher,S. Grant,K. Hellestrand,M. Kava,Leonard Kritharides,D. McGill,H. McKee,Allan J. McLean,M. Neaverson,G. Nelson,M. O'Neill,C. Onuma,F. O'Reilly +98 more
TL;DR: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
5.5K
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Helen M. Colhoun,D. John Betteridge,Paul N. Durrington,Graham A. Hitman,H. Andrew W. Neil,Shona Livingstone,Margaret J Thomason,Michael I. Mackness,Valentine Charlton-Menys,John H. Fuller +9 more
TL;DR: Atorvastatin 10 mg daily is safe and efficacious in reducing the risk of first cardiovascular disease events, including stroke, in patients with type 2 diabetes without high LDL-cholesterol.
3.9K
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Peter S. Sever,Björn Dahlöf,Neil R Poulter,Hans Wedel,Gareth Beevers,Mark J. Caulfield,Rory Collins,Sverre E. Kjeldsen,Arni Kristinsson,Gordon T. McInnes,Jesper Mehlsen,Markku S. Nieminen,Eoin O'Brien,Jan Östergren +13 more
TL;DR: The reductions in major cardiovascular events with atorvastatin are large, given the short follow-up time, and may have implications for future lipid-lowering guidelines.
3.7K
Cerebral vascular accidents in patients over the age of 60. II. Prognosis.
TL;DR: A survey was carried out on a number of 'untreated' cases seen shortly after the onset of a cerebral vascular accident, with particular reference to the presence of signs which had prognostic value, to enable the investigator to assess the results of specific forms of treatment.
2.5K
Related Papers (5)
Walter N. Kernan,Bruce Ovbiagele,Henry R. Black,Dawn M. Bravata,Marc I. Chimowitz,Michael D. Ezekowitz,Margaret C. Fang,Marc Fisher,Karen L. Furie,Donald V. Heck,S. Claiborne Johnston,Scott E. Kasner,Steven J. Kittner,Pamela H. Mitchell,Michael W. Rich,DeJuran Richardson,Lee H. Schwamm,John A. Wilson +17 more
Andrew Tonkin,P. Alyward,David Colquhoun,Paul Glasziou,P. Harris,D. Hunt,Anthony C Keech,Stephen MacMahon,P. Magnus,D. Newel,P. Nestel,N. Sharpe,J. Shaw,R. J. Simes,P. Thompson,Alexis A. Thompson,Malcolm J. West,H. White,S. Simes,Wendy Hague,Sue Caleo,Jane Hall,Andrew J. Martin,S. Mulray,Philip J. Barter,Lawrence J. Beilin,Rory Collins,John J McNeil,Petra Meier,H. Willimott,D. Smithers,P. Wallace,J. Baker,M. Hobbs,David R. Sullivan,N. Anderson,Graeme J. Hankey,John D.G. Watson,M. Arulchelvam,S. Chup,John Daly,J. Hanna,A. Leach,M. Lee,J. Loughhead,H. Lundie-Jenkin,J. Morrison,S. Netting,A. Nguyen,H. Pater,R. Philip,G. Pinna,D. Rattos,S. Ryerson,V. Sazhin,Richard Walsh,A. Claque,M. Mackie,Julie Jane Yallop,K. Boss,M. Shepard,J. Leach,M. Gandy,J. Joughin,J. Seabrook,R. Abraham,J. Allen,F. Bates,I. Beinart,E. Breed,D. Brown,N. Bunyan,D. Calvert,T. Campbell,D. Condon-Paoloni,B. Conway,Lucy A. Coupland,J. Crowe,N. Cunio,B. Cuthbert,N. Cuthbert,S. D'Arcy,Patricia M. Davidson,B. Dwyer,J. England,C. Friend,Greg Fulcher,S. Grant,K. Hellestrand,M. Kava,Leonard Kritharides,D. McGill,H. McKee,Allan J. McLean,M. Neaverson,G. Nelson,M. O'Neill,C. Onuma,F. O'Reilly +98 more